---
title: 'Medical Director at Attovia Therapeutics'
canonical: 'https://feeny.ai/job/medical-director-attovia-therapeutics-san-carlos-wvtrgawqmqne'
type: 'job'
last_seen: '2026-09-11'
---

# Medical Director at Attovia Therapeutics

- **Company:** Attovia Therapeutics
- **Location:** San Carlos, CA
- **Compensation:** $280k–$315k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-04-27
- **Last confirmed live:** 2026-09-11
- **Apply:** https://jobs.lever.co/attovia-therapeutics/743fa705-21f0-429b-8a36-6e3e5a7a1506

## Job description

The position of Medical Director will be an essential part of the clinical development team and will report to the Chief Medical Officer. The Medical Director will be responsible for the design and execution of clinical studies at Attovia. This individual will partner closely with Clinical Science, Clinical Operations, Regulatory, and other cross-functional team members to ensure the successful development of Attobody-based therapeutics. Attovia’s rapidly expanding pipeline includes multiple first-in-human and early proof-of-concept studies for immune-mediated diseases.

## Key Responsibilities

- Lead cross-functional study teams in the design, implementation, analysis, and interpretation of clinical trials. Ensure that project deliverables are accomplished on time and within budget.
- Assist in authoring clinical-regulatory documents, including study protocols, investigator brochures, IND/CTAs, informed consents, clinical study reports, procedure manuals, statistical analysis plans, and briefing documents for health authorities.
- Act as the medical monitor for Attovia clinical trials. Conduct regular medical safety data reviews.  Identify, manage, and communicate potential safety signals.
- Prepare and deliver presentations and other scientific communications for internal and external stakeholders, including clinical advisors and study investigators.
- Engage with key opinion leaders to gain medical insights, inform clinical development plans, and build awareness and enthusiasm for Attovia’s programs.
- Organize and conduct clinical/scientific advisory board meetings as needed.
- Partner with Clinical Science and Clinical Operations to identify and build strong professional relationships with study investigators.
- Partner with Clinical Operations to identify, select, and manage CROs, study sites, and clinical vendors.
- Serve as the medical knowledge expert in target indication(s), develop target product profiles, and contribute to clinical and regulatory strategy.
- Partner with Project Management to ensure that clinical activities, timelines, and budgets are aligned with overall corporate goals.

## Qualifications

- MD with a minimum of 4 years of clinical drug development. Active medical license preferred.
- Ability to work in a fast-paced, small biotech environment.
- Ability to interpret medical safety data independently without additional oversight.
- Exceptional written and verbal communication skills as evidenced by publications and platform presentations at scientific meetings.
- Proven track record of successful design and implementation of clinical trials. Prior experience in early-stage drug development (Phase 1 to 2) strongly preferred.
- Demonstrated leadership presence, with the ability to foster relationships with key opinion leaders, study investigators, and academic collaborators.
- Therapeutic experience in immune-mediated diseases. Expertise in inflammatory bowel disease is preferred but not required.
- Strong analytical skills with the ability to interpret complex data sets and make informed decisions.
- Familiarity with the general principles of pharmacology/toxicology as it relates to first-in-human studies and early drug development.
- Proactive personality, positive/solution-oriented mindset, careful attention to detail, adaptability to rapidly changing environment, and high ethical standards.
- Willingness to travel intermittently for conferences, investigator meetings, and advisory boards.
- Willingness to work in-office at least 4 days per week and relocate if necessary.

## About Attovia

Attovia is creating a pipeline of biotherapeutics with initial focus immune-mediated disease. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that expand the addressable target universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile than traditional approaches. We are currently progressing multiple programs across immune-mediated disease indications.

Our culture is centered around five core pillars:

- Integrity
- Learning & Growth
- Drive for Excellence
- Innovation
- Teamwork & Collaboration

We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace.

Attovia is located in San Carlos, CA.

Attovia is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

Learn more about Attovia: [www.attovia.com](http://www.attovia.com)

## About Attovia Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY biparatopic biologics platform.
- **Entity Type**: Private (S-1 filed for IPO)
- **Headquarters**: San Carlos, California, USA
- **Founded**: 2023
- **Founders**: Founded by a group of investors including Alamar Biosciences, Inc. (individual founders not publicly named)

## Core Business
- **Primary industry/industries**: Biopharmaceuticals, immune-mediated diseases (dermatology, gastroenterology/IBD, respiratory)
- **Target customers**: B2B (potential partnerships with larger pharma); ultimately patients with high unmet medical need
- **Mission or purpose statement**: To develop new and improved treatments for patients in need by combining scientific curiosity with impactful change, leveraging the ATTOBODY platform to design novel complex biologics.

## Products & Services
- **ATTOBODY Platform**: Proprietary evolution-driven, high-throughput discovery platform that creates biparatopic (two VHH domains) biologics with ultra-high affinity, modularity, and the ability to target two, three, or four disease-driving pathways in a single molecule. Designed for rapid candidate generation and de-risked development.
- **ATTO-1310**: Monospecific ATTOBODY targeting IL-31. Completed Phase 1 clinical trial dosing in healthy volunteers and patients (Q1 2026). Indications: chronic pruritus, atopic dermatitis, chronic pruritus of unknown origin, cholestatic pruritus, CKD-associated pruritus.
- **ATTO-2306**: Bispecific ATTOBODY targeting IL-13 and IL-31. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory skin diseases (atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis).
- **ATTO-1091**: Trispecific ATTOBODY-based Fc-fusion protein targeting TL1A, IL-23p19, and integrin α4β7. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory bowel disease (ulcerative colitis, Crohn’s disease).
- **Early-stage pipeline (ATTO-006, ATTO-007, ATTO-008)**: Pre-discovery programs targeting T<sub>RM</sub> survival, immune cell survival, and multi-alarmin blockade for rheumatology, IBD, respiratory (asthma, COPD).

## Market Standing
- **Valuation/Market Cap**: Not disclosed (private; S-1 filed indicates intent to raise capital via IPO)
- **Key Metric**: Total funding not publicly disclosed; S-1 filing represents first public financial disclosure. The company is pre-revenue (clinical-stage).
- **Notable Investors/Partners**: Alamar Biosciences (in-licensor of ATTOBODY platform). Additional founding investors not named in public filings.
- **Growth Signals**: Completed Phase 1 for lead candidate ATTO-1310 within ~2 years of founding; headcount grew 35.9% year-over-year to ~40 employees; pipeline expanding into three therapeutic areas with three candidates in IND-enabling studies.

## Competitive Advantages
- **ATTOBODY platform differentiator**: Biparatopic binding enables ultra-high affinity and potency, tunable pharmacokinetics, and modular design for multispecifics (bispecifics, trispecifics, conditional “AND” gate biologics).
- **Speed of discovery**: Evolution-based high-throughput screening allows rapid nomination of multiple candidates (three within first two years).
- **Targeting clinically validated pathways**: Focus on pathways with proven commercial and clinical precedent (IL-31, IL-13, TL1A, IL-23, integrin α4β7), reducing biological risk.
- **Robust drug-like properties**: ATTOBODIES exhibit IgG-like stability and developability, potentially enabling infrequent dosing.

## Strategic Focus
- Advance ATTO-1310 through clinical development for pruritus and atopic dermatitis.
- Progress ATTO-2306 and ATTO-1091 into Phase 1 trials in 2027.
- Expand early-stage pipeline into respiratory and additional inflammatory indications.
- Leverage platform to create next-generation complex biologics that improve upon current standards of care.
- Execute IPO to fund pipeline advancement and platform expansion.

## Why Work Here
- **Culture**: Values-driven environment emphasizing integrity, continuous learning, drive for excellence, innovation, and teamwork. Described as a community of passionate scientists, inspiring leaders, and visionary executives.
- **Benefits**: Comprehensive medical/dental/vision with company premium contributions, FSA/HSA, competitive PTO and sick leave, supplemental parental leave, commute assistance, 401(k) with employer match (immediate vesting), equity grants, educational assistance, and mentorship program.
- **Work environment**: Likely on-site in San Carlos, CA (no explicit remote/hybrid policy stated). Small but rapidly growing team (~40 employees) with a flat, collaborative structure.
- **Engineering/Research culture**: High autonomy, data-driven decision-making, and focus on transformative science. Employees are encouraged to push boundaries and drive progress.

## Sources
1. [linkedin.com](https://linkedin.com/company/attovia-therapeutics) – Employee data, executives, growth
2. [attovia.com](https://www.attovia.com/careers/) – Careers page, culture, benefits
3. [attovia.com](https://www.attovia.com/pipeline/) – Pipeline overview, platform description
4. [sec.gov](https://www.sec.gov/Archives/edgar/data/2058707/000119312526303256/d40469ds1.htm) – S-1 filing, business description, financials
5. [cbinsights.com](https://www.cbinsights.com/company/attovia-therapeutics) – Profile summary, founding year, headquarters

## Other roles at Attovia Therapeutics

- [Head of IR](https://feeny.ai/job/head-of-ir-attovia-therapeutics-san-carlos-gzaqh4z58m0y) — San Carlos, CA
- [Medical Director](https://feeny.ai/job/medical-director-daymark-health-los-angeles-k3vqyy8mf7c7) — Los Angeles, CA
- [Medical Director](https://feeny.ai/job/medical-director-daymark-health-detroit-1b28p6we13g7) — Detroit, MI
- [Medical Director](https://feeny.ai/job/medical-director-prenuvo-dubai-jn6mdpwb67sf) — Dubai, United Arab Emirates
- [Medical Director](https://feeny.ai/job/medical-director-copilotiq-remote-vz8a8gjvhxgd)
- [Medical Director](https://feeny.ai/job/medical-director-apothecom-yardley-szcd8t5awsh7) — Yardley, PA
- [Medical Director](https://feeny.ai/job/medical-director-inizio-evoke-new-york-pv072nqzd7az) — New York, NY
- [Medical Director](https://feeny.ai/job/medical-director-honeydew-remote-81t71465y0x8)
- [Medical Director](https://feeny.ai/job/medical-director-phasev-one-broadway-11th-floor-cambridge-ma-02142-g19j9srx1h92) — One Broadway 11th Floor Cambridge MA 02142, United States
- [Medical Director](https://feeny.ai/job/medical-director-hopscotch-primary-care-marion-0akr5wacd3nb) — Marion, NC